Visual Abstract

Introduction: The additive benefit of interleukin-2 receptor antagonist (IL2-RA) induction in standard-risk kidney transplant recipients, while maintained on tacrolimus-based immunosuppressive therapy, is uncertain. Methods: We divided the studies included in this meta-analysis into 2 groups: group A (included studies that used same dose of tacrolimus in both arms of each study) and group B (included studies that compared patients who received induction therapy and low-dose tacrolimus vs. those who received no-induction therapy and high dose of tacrolimus). Results: In group A, 11 studies were included (n = 2,886). IL2-RA induction therapy was not associated with significant differences in comparison to no-induction therapy in terms of acute rejection rates at 6 months post-transplant (risk ratio = 1.12 and 95% confidence interval [CI] range: 0.94–1.35) or graft survival at 1 year post-transplant (risk ratio = 0.78 and 95% CI range: 0.45–1.36). In group B, 2 studies were included (n = 669). There was no difference between both arms in terms of acute rejection rates (risk ratio = 0.62, with 95% CI range: 0.33–1.14) or graft survival (risk ratio = 1 and 95% CI range: 0.57–1.74). Conclusion: IL2-RA induction therapy does not improve outcomes in patients maintained on tacrolimus-based immunotherapy in standard-risk population.

2.
Kidney Disease: Improving Global Outcomes Transplant Work G
.
KDIGO clinical practice guideline for the care of kidney transplant recipients
.
Am J Transplant
.
2009
;
9
(
Suppl 3
):
S1
155
. .
3.
Baker
R
,
Jardine
A
,
Andrews
P
.
Renal association clinical practice guideline on post-operative care of the kidney transplant recipient
.
Nephron Clin Pract
.
2011
;
118
(
Suppl 1
):
c311
47
. .
4.
Webster
AC
,
Ruster
LP
,
McGee
R
,
Matheson
SL
,
Higgins
GY
,
Willis
NS
, et al
Interleukin 2 receptor antagonists for kidney transplant recipients
.
Cochrane Database Syst Rev
.
2010 Jan 20
;
2010
(
1
):
CD003897
. .
5.
Webster
AC
,
Woodroffe
RC
,
Taylor
RS
,
Chapman
JR
,
Craig
JC
.
Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data
.
BMJ
.
2005
;
331
(
7520
):
810
.
6.
Kliem
V
,
Brunkhorst
R
.
Tacrolimus in kidney transplantation. A clinical review
.
Nephron
.
1998
;
79
(
1
):
8
20
. .
7.
Jindal
RM
,
Das
NP
,
Neff
RT
,
Hurst
FP
,
Falta
EM
,
Elster
EA
, et al
Outcomes in African-Americans versus caucasians using thymoglobulin or interleukin-2 receptor inhibitor induction: analysis of USRDS database
.
Am J Nephrol
.
2009
;
29
:
501
8
.
8.
Prasad
GV
,
Nash
MM
,
McFarlane
PA
,
Zaltzman
JS
,
Zaltzman
JS
.
A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors
.
Nephron Clin Pract
.
2004
;
97
(
2
):
c35
40
. .
9.
Issa
N
,
Kukla
A
,
Ibrahim
HN
.
Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence
.
Am J Nephrol
.
2013
;
37
(
6
):
602
12
. .
10.
Al Dhaybi
O
,
Bakris
G
.
New onset hypertension linked to generic cyclosporine substitution in post-renal transplant patient
.
Am J Nephrol
.
2016
;
44
(
3
):
219
23
. .
11.
Shah
PB
,
Ennis
JL
,
Cunningham
PN
,
Josephson
MA
,
McGill
RL
.
The epidemiologic burden of tacrolimus variability among kidney transplant recipients in the United States
.
Am J Nephrol
.
2019
;
50
:
370
4
.
12.
Martins
L
,
Ventura
A
,
Branco
A
,
Carvalho
MJ
,
Henriques
AC
,
Dias
L
, et al
Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity?
Transplant Proc
.
2004
;
36
(
4
):
877
9
. .
13.
Ekberg
H
,
Grinyó
J
,
Nashan
B
,
Vanrenterghem
Y
,
Vincenti
F
,
Voulgari
A
, et al
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study
.
Am J Transplant
.
2007
;
7
(
3
):
560
70
. .
14.
Liu
J-yu
,
You
R-xu
,
Guo
M
,
Zeng
L
,
Zhou
P
,
Zhu
L
, et al
Tacrolimus versus cyclosporine as primary immunosuppressant after renal transplantation: a meta-analysis and economics evaluation
.
Am J Ther
.
May–June 2016
;
23
(
3
):
e810
e824
.
15.
Azarfar
A
,
Ravanshad
Y
,
Mehrad-Majd
H
,
Esmaeeli
M
,
Aval
SB
,
Emadzadeh
M
, et al
Comparison of tacrolimus and cyclosporine for immunosuppression after renal transplantation: an updated systematic review and meta-analysis
.
Saudi J Kidney Dis Transpl
.
2018 Nov–Dec
;
29
(
6
):
1376
85
. .
16.
Hellemans
R
,
Bosmans
JL
,
Abramowicz
D
.
Induction therapy for kidney transplant recipients: do we still need anti-il2 receptor monoclonal antibodies?
Am J Transplant
.
2017
;
17
(
1
):
22
7
. .
17.
Ali
H
,
Sharma
A
,
Halawa
A
.
Effect of interleukin-2 receptor antibody induction therapy on survival in renal transplant patients receiving tacrolimus
.
Am J Nephrol
.
2020
;
51
(
5
):
366
72
.
18.
Lim
WH
,
Chadban
SJ
,
Campbell
S
,
Dent
H
,
Russ
GR
,
McDonald
SP
.
Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients
.
Transpl Int
.
2010 Dec
;
23
(
12
):
1207
15
.
19.
Tanriover
B
,
Jaikaransingh
V
,
MacConmara
MP
,
Parekh
JR
,
Levea
SL
,
Ariyamuthu
VK
, et al
Acute rejection rates and graft outcomes according to induction regimen among recipients of kidneys from deceased donors treated with tacrolimus and mycophenolate
.
Clin J Am Soc Nephrol
.
2016
;
11
(
9
):
1650
61
. .
20.
Tanriover
B
,
Zhang
S
,
MacConmara
M
,
Gao
A
,
Sandikci
B
,
Ayvaci
MU
, et al
Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance
.
Clin J Am Soc Nephrol
.
2015
;
10
(
6
):
1041
9
. .
21.
Ali
H
,
Mohiuddin
A
,
Sharma
A
,
Shaheen
I
,
Kim
JJ
,
El Kosi
M
.
Implication of interleukin-2 receptor antibody induction therapy in risk renal transplant in the tacrolimus era: a meta-analysis
.
Clin Kidney J
.
2019 Aug
;
12
(
4
):
592
99
. .
22.
Nice Health Care Database Advance Search
.
New search strategy: healthcare databases advanced search
.
2019 Jul 21
. Available at: https://hdas.nice.org.uk/.
23.
Clarke
M
,
Horton
R
.
Bringing it all together: lancet-cochranecollaborate on systematic reviews
.
Lancet
.
2001
;
357
(
9270
):
1728
.
24.
Stroup
DF
,
Berlin
JA
,
Morton
SC
,
Olkin
I
,
Williamson
GD
,
Rennie
D
, et al
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group
.
JAMA
.
2000
;
283
(
15
):
2008
. .
25.
StataCorp
.
2017
.
Stata 15 Base Reference Manual
.
College Station, TX: Stata
Press
.
26.
Ahsan
N
,
Holman
MJ
,
Jarowenko
MV
,
Razzaque
MS
,
Yang
HC
.
Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation
.
Am J Transplant
.
2002
;
2
(
6
):
568
73
. .
27.
Kuypers
DR
,
Evenepoel
P
,
Maes
B
,
Coosemans
W
,
Pirenne
J
,
Vanrenterghem
Y
.
The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients
.
Clin Transplant
.
2003
;
17
(
3
):
234
41
. .
28.
ter Meulen
CG
,
van Riemsdijk
I
,
Hené
RJ
,
Christiaans
MH
,
Borm
GF
,
van Gelder
T
, et al
Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study
.
Am J Transplant
.
2004
;
4
(
5
):
803
10
. .
29.
Wilson
CH
,
Brook
NR
,
Gok
MA
,
Asher
JF
,
Nicholson
ML
,
Talbot
D
.
Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants
.
Br J Surg
.
2005
;
92
(
6
):
681
7
. .
30.
Rostaing
L
,
Cantarovich
D
,
Mourad
G
,
Budde
K
,
Rigotti
P
,
Mariat
C
, et al
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation
.
Transplantation
.
2005
;
79
(
7
):
807
14
. .
31.
Cheung
CY
,
Liu
YL
,
Wong
KM
,
Chan
HW
,
Chan
YH
,
Wong
HS
, et al
Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
Nephrology
.
2008
;
13
(
3
):
251
5
. .
32.
Krämer
BK
,
Klinger
M
,
Vítko
Š
,
Glyda
M
,
Midtvedt
K
,
Stefoni
S
, et al
Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial
.
Transplantation
.
2012
;
94
(
5
):
492
8
. .
33.
Vítko
S
,
Klinger
M
,
Salmela
K
,
Wlodarczyk
Z
,
Tydèn
G
,
Senatorski
G
, et al
Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study
.
Transplantation
.
2005
;
80
(
12
):
1734
41
.
34.
Sugiyama
K
,
Isogai
K
,
Horisawa
S
,
Toyama
A
,
Satoh
H
,
Saito
K
, et al
Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab
.
Cell Transplant
.
2012
;
21
(
2–3
):
565
70
. .
35.
Gundlapalli
S
,
Rathi
M
,
Kohli
HS
,
Jha
V
,
Sharma
A
,
Minz
M
, et al
Efficacy of basiliximab induction in poorly matched living donor renal transplantation
.
Indian J Nephrol
.
2013
;
23
(
6
):
409
12
. .
36.
Albano
L
,
Banas
B
,
Klempnauer
JL
,
Glyda
M
,
Viklicky
O
,
Kamar
N
, et al
OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation
.
Transplantation
.
2013
;
96
(
10
):
897
903
.
37.
Baek
CH
,
Kim
JH
,
Yu
H
,
Shin
E
,
Cho
H
,
Kim
H
, et al
Usefulness of tacrolimus without basiliximab in well-matched living-donor renal transplant recipients in Korea
.
Exp Clin Transplant
.
2016
;
14
(
4
):
389
93
. .
38.
Bansal
S
,
Pathania
D
,
Sethi
S
,
Jha
P
,
Nandwani
A
,
Jain
M
, et al
Basiliximab induction in living donor kidney transplant with tacrolimus-based triple immunosuppression
.
Indian J Transplant
.
2019
;
13
(
2
):
104
. .
39.
Willoughby
LM
,
Schnitzler
MA
,
Brennan
DC
,
Pinsky
BW
,
Dzebisashvili
N
,
Buchanan
PM
, et al
Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons
.
Transplantation
.
2009
;
87
(
10
):
1520
9
. .
40.
Zsom
L
,
Wagner
L
,
Fülöp
T
.
Minimization vs tailoring: where do we stand with personalized immunosuppression during renal transplantation in 2015?
World J Transplant
.
2015 Sep 24
;
5
(
3
):
73
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.